Table 1: LHRH agonists and new generation antagonists available in the market.

PeptideSequence comparisonIndications

Agonists
 BuserelinPyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-NHEtProstate cancer
 GonadorelinPyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2Cystic ovarian disease, agent for evaluating hypothalamic-pituitary gonadotropic function
 GoserelinPyr-His-Trp-Ser-Tyr-D-Ser(OtBu)-Leu-Arg-Pro-AzGly-NH2Prostate cancer; breast cancer
 HistrelinPyr-His-Trp-Ser-Tyr-D-His(N-benzyl)-Leu-Arg-Pro-NHEtProstate cancer; breast cancer
 LeuprolidePyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtProstate cancer; breast cancer
 NafarelinPyr-His-Trp-Ser-Tyr-2Nal-Leu-Arg-Pro-Gly-NH2Treat symptoms of endometriosis, central precocious puberty
 TriptorelinPyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH2Prostate cancer; breast cancer

Antagonists
 AbarelixAc-D-2Nal-D-4-chloroPhe-D-3-(3′-pyridyl) Ala-Ser-(N-Me)Tyr-D-Asn-Leu-isopropylLys-Pro-DAla-NH2Prostate cancer
 CetrorelixAc-D-2Nal-D-4-chloroPhe-D-3-(3′-pyridyl) Ala-Ser-Tyr-D-Cit-Leu-Arg-Pro-D-Ala-NH2Prostate cancer; breast cancer
 DegarelixAc-D-2Nal-D-4-chloroPhe-D-3-(3′-pyridyl) Ala-Ser-4-aminoPhe(L-hydroorotyl)-D-4-aminoPhe(carbamoyl)-Leu-isopropylLys-Pro-D-Ala-NH2Prostate cancer
 GanirelixAc-D-2Nal-D-4-chloroPhe-D-3-(3′-pyridyl) Ala-Ser-Tyr-D-(N9, N10-diethyl)-homoArg-Leu-(N9, N10-diethyl)-homoArg-Pro-D-Ala-NH2Fertility treatment